V1RC17 Inhibitors
V1RC17 inhibitors represent a category of chemical agents characterized by their specific interaction with the V1RC17 receptor, a protein associated with various biochemical processes within cellular environments. The precise nature of these inhibitors is defined by their ability to bind to the V1RC17 receptor, thereby modulating its activity. This modulation is achieved through a complex interplay of molecular interactions, which can result in the inhibition of the receptor's function. The design of V1RC17 inhibitors is a sophisticated process that takes into consideration the structural and functional nuances of the receptor, aiming to produce compounds that exhibit high specificity and selectivity towards V1RC17. This specificity is critical, as it reduces the likelihood of off-target effects that could arise from interactions with other similar receptors within the same family or different biological pathways.
Chemically, V1RC17 inhibitors are diverse, encompassing a range of molecular frameworks that can include small molecules, peptides, or other macromolecular constructs. These inhibitors are crafted through a detailed understanding of the receptor's ligand-binding domain, which is essential for the receptor's activation or inhibition. The ligand-binding domain offers a blueprint for the development of inhibitors that can snugly fit into the receptor's active site or allosteric sites, thus preventing the receptor from engaging in its normal interactions with its natural ligands. This inhibition is achieved by either competitive or non-competitive means, with the former involving direct competition with the natural ligand for binding sites, and the latter involving binding to distinct sites that induce conformational changes in the receptor, reducing its activity. The molecular intricacies of V1RC17 inhibitors are further explored through a variety of analytical techniques, including X-ray crystallography, NMR spectroscopy, and computational modeling, which together provide a detailed picture of the inhibitor-receptor interaction.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor. V1RC17, being downstream of EGFR signaling, is functionally inhibited as Erlotinib reduces EGFR's kinase activity, leading to diminished signal transduction and decreased V1RC17 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. It prevents the activation of mTORC1, which is essential for protein synthesis and cell growth. This action indirectly decreases V1RC17 function, as V1RC17 may be dependent on mTOR-mediated pathways for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents the phosphorylation and activation of AKT. Inhibition of this pathway results in reduced activity of downstream effectors, including V1RC17, leading to its functional inhibition. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is a selective EGFR inhibitor effective against T790M mutants. By blocking EGFR activity, it indirectly inhibits downstream pathways that would otherwise contribute to the functional activation of V1RC17. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor that arrests cell cycle progression. This inhibition may reduce the availability of factors necessary for V1RC17 functionality, thus indirectly leading to its decreased activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that impedes the MAPK/ERK pathway. Since V1RC17 activity can be modulated by ERK signaling, inhibition of this pathway results in reduced V1RC17 function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple tyrosine protein kinases, such as VEGFR, PDGFR, and Raf kinases. Its action on these pathways indirectly hampers the signaling processes that could contribute to V1RC17 activation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets HER2 and EGFR. Inhibiting these receptors can lead to the functional inhibition of V1RC17 by reducing the downstream signaling that would normally enhance V1RC17 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that leads to the accumulation of misfolded proteins, potentially disrupting the cellular environment necessary for V1RC17 activity. As a result, V1RC17 functionality is indirectly diminished. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, preventing the activation of the MAPK/ERK pathway. This inhibition can reduce V1RC17 activity by limiting the downstream signaling that enhances V1RC17 function. | ||||||